THE INFLUENCE OF GENETIC POLYMORPHISMS BCL-2 AND C-MYC IN PATIENTS WITH DLBCL TREATED WITH RCHOP TO ACHIEVE COMPLETE REMISSION
(Abstract release date: 05/19/16)
EHA Library. Sretenovic S. 06/09/16; 134591; PB1691
Dr. Snezana Sretenovic
Contributions
Contributions
Abstract
Abstract: PB1691
Type: Publication Only
Background
Non -Hodgkin's diffuse large B- cell lymphoma ( DLBCL) represents a heterogeneous group of aggressive lymphomas, which are characterized by the presence of large, transformed B cells. DLBCL with both translocations C-MYC and BCL-2 provides double-hit lymphoma and is characterized by poor response to standard therapy with an aggressive clinical course.
Aims
What is the influence of BCL-2 and C-MYC in DLBCL treated with RCHOP to achive complete remission.
Methods
We analyzed the population of 62 patients primary DLBCL, treated with immunochemotherapy R-CHOP/21 day. Testing BCL-2 and C-MYC was conducted with classical FISH analysis. Complete remission (CR) was defined as the absence of disease after the therapy. We tested the sensitivity and specificity, and statistical analysis was performed in Windows SSPS (22.00), a statistical significance defined as p <0,05.
Results
The study group consisted of 32 men and 30 women, mean age was 59.76 +/- 14,38. The patients were in CS III and IV in 81.9%. After applying the first therapeutic line RCHOP, 30 patients or 48.7% achieved a complete remission. The frequency of FISH / BCL2+ in the group with complete remission was 40% and in the group without a complete remission of 46.2%. Achieving complete remission was not statistically significantly different between subjects FISH/ BCL-2 positive and negative (χ 2 test, p = 0,585). Frequency FISH/C-MYC in the group with complete remission was 36.7%, while in the group without CR it was 43.8%. Achieving complete remission was not significantly different between patients FISH/ C-MYC positive and negative (χ 2 test, p = 0,570). The frequency of both positive FISH/ BCL-2 and C-MYC, with the presence of at least one positive polymorphism and negative both, it is not statistically significantly different in comparison to achieving a complete remission (χ 2 test, p=0,600). Respondents with BCL-2 and C-MYC negative were slightly over-represented in the group with the complete remission of 43,3%, compared to the patients without complete remission of 31,3%. A bit higher frequency BCL-2 positive patients 31,3% was observed in group without achieving the complete remission, but in patients with complete remission of 20%. The sensitivity observed in the presence of both polymorphisms as well as the sensitivity of FISH positive BCL-2 or C-MYC findings was the same, about 45%. Specificity was the same in the presence BCL-2 or C-MYC gene polymorphism at about 60%, while it was the lowest in the presence both genetic polymorphism
Conclusion
In our study, the sensitivity observed in the presence of both or single mutation was the same, about 45%. Specificity in all observed parameters was relatively small, which means that the absence of the observed risk factors does not mean the emergence of the complete remission. The existence C-MYC and BCL-2 is not a good predictor of achieving complete remission in the era of rituximab.
Session topic: E-poster
Keyword(s): BCL2, C-myc, Fluorescence in situ hybridization, Remission
Type: Publication Only
Background
Non -Hodgkin's diffuse large B- cell lymphoma ( DLBCL) represents a heterogeneous group of aggressive lymphomas, which are characterized by the presence of large, transformed B cells. DLBCL with both translocations C-MYC and BCL-2 provides double-hit lymphoma and is characterized by poor response to standard therapy with an aggressive clinical course.
Aims
What is the influence of BCL-2 and C-MYC in DLBCL treated with RCHOP to achive complete remission.
Methods
We analyzed the population of 62 patients primary DLBCL, treated with immunochemotherapy R-CHOP/21 day. Testing BCL-2 and C-MYC was conducted with classical FISH analysis. Complete remission (CR) was defined as the absence of disease after the therapy. We tested the sensitivity and specificity, and statistical analysis was performed in Windows SSPS (22.00), a statistical significance defined as p <0,05.
Results
The study group consisted of 32 men and 30 women, mean age was 59.76 +/- 14,38. The patients were in CS III and IV in 81.9%. After applying the first therapeutic line RCHOP, 30 patients or 48.7% achieved a complete remission. The frequency of FISH / BCL2+ in the group with complete remission was 40% and in the group without a complete remission of 46.2%. Achieving complete remission was not statistically significantly different between subjects FISH/ BCL-2 positive and negative (χ 2 test, p = 0,585). Frequency FISH/C-MYC in the group with complete remission was 36.7%, while in the group without CR it was 43.8%. Achieving complete remission was not significantly different between patients FISH/ C-MYC positive and negative (χ 2 test, p = 0,570). The frequency of both positive FISH/ BCL-2 and C-MYC, with the presence of at least one positive polymorphism and negative both, it is not statistically significantly different in comparison to achieving a complete remission (χ 2 test, p=0,600). Respondents with BCL-2 and C-MYC negative were slightly over-represented in the group with the complete remission of 43,3%, compared to the patients without complete remission of 31,3%. A bit higher frequency BCL-2 positive patients 31,3% was observed in group without achieving the complete remission, but in patients with complete remission of 20%. The sensitivity observed in the presence of both polymorphisms as well as the sensitivity of FISH positive BCL-2 or C-MYC findings was the same, about 45%. Specificity was the same in the presence BCL-2 or C-MYC gene polymorphism at about 60%, while it was the lowest in the presence both genetic polymorphism
Conclusion
In our study, the sensitivity observed in the presence of both or single mutation was the same, about 45%. Specificity in all observed parameters was relatively small, which means that the absence of the observed risk factors does not mean the emergence of the complete remission. The existence C-MYC and BCL-2 is not a good predictor of achieving complete remission in the era of rituximab.
Session topic: E-poster
Keyword(s): BCL2, C-myc, Fluorescence in situ hybridization, Remission
Abstract: PB1691
Type: Publication Only
Background
Non -Hodgkin's diffuse large B- cell lymphoma ( DLBCL) represents a heterogeneous group of aggressive lymphomas, which are characterized by the presence of large, transformed B cells. DLBCL with both translocations C-MYC and BCL-2 provides double-hit lymphoma and is characterized by poor response to standard therapy with an aggressive clinical course.
Aims
What is the influence of BCL-2 and C-MYC in DLBCL treated with RCHOP to achive complete remission.
Methods
We analyzed the population of 62 patients primary DLBCL, treated with immunochemotherapy R-CHOP/21 day. Testing BCL-2 and C-MYC was conducted with classical FISH analysis. Complete remission (CR) was defined as the absence of disease after the therapy. We tested the sensitivity and specificity, and statistical analysis was performed in Windows SSPS (22.00), a statistical significance defined as p <0,05.
Results
The study group consisted of 32 men and 30 women, mean age was 59.76 +/- 14,38. The patients were in CS III and IV in 81.9%. After applying the first therapeutic line RCHOP, 30 patients or 48.7% achieved a complete remission. The frequency of FISH / BCL2+ in the group with complete remission was 40% and in the group without a complete remission of 46.2%. Achieving complete remission was not statistically significantly different between subjects FISH/ BCL-2 positive and negative (χ 2 test, p = 0,585). Frequency FISH/C-MYC in the group with complete remission was 36.7%, while in the group without CR it was 43.8%. Achieving complete remission was not significantly different between patients FISH/ C-MYC positive and negative (χ 2 test, p = 0,570). The frequency of both positive FISH/ BCL-2 and C-MYC, with the presence of at least one positive polymorphism and negative both, it is not statistically significantly different in comparison to achieving a complete remission (χ 2 test, p=0,600). Respondents with BCL-2 and C-MYC negative were slightly over-represented in the group with the complete remission of 43,3%, compared to the patients without complete remission of 31,3%. A bit higher frequency BCL-2 positive patients 31,3% was observed in group without achieving the complete remission, but in patients with complete remission of 20%. The sensitivity observed in the presence of both polymorphisms as well as the sensitivity of FISH positive BCL-2 or C-MYC findings was the same, about 45%. Specificity was the same in the presence BCL-2 or C-MYC gene polymorphism at about 60%, while it was the lowest in the presence both genetic polymorphism
Conclusion
In our study, the sensitivity observed in the presence of both or single mutation was the same, about 45%. Specificity in all observed parameters was relatively small, which means that the absence of the observed risk factors does not mean the emergence of the complete remission. The existence C-MYC and BCL-2 is not a good predictor of achieving complete remission in the era of rituximab.
Session topic: E-poster
Keyword(s): BCL2, C-myc, Fluorescence in situ hybridization, Remission
Type: Publication Only
Background
Non -Hodgkin's diffuse large B- cell lymphoma ( DLBCL) represents a heterogeneous group of aggressive lymphomas, which are characterized by the presence of large, transformed B cells. DLBCL with both translocations C-MYC and BCL-2 provides double-hit lymphoma and is characterized by poor response to standard therapy with an aggressive clinical course.
Aims
What is the influence of BCL-2 and C-MYC in DLBCL treated with RCHOP to achive complete remission.
Methods
We analyzed the population of 62 patients primary DLBCL, treated with immunochemotherapy R-CHOP/21 day. Testing BCL-2 and C-MYC was conducted with classical FISH analysis. Complete remission (CR) was defined as the absence of disease after the therapy. We tested the sensitivity and specificity, and statistical analysis was performed in Windows SSPS (22.00), a statistical significance defined as p <0,05.
Results
The study group consisted of 32 men and 30 women, mean age was 59.76 +/- 14,38. The patients were in CS III and IV in 81.9%. After applying the first therapeutic line RCHOP, 30 patients or 48.7% achieved a complete remission. The frequency of FISH / BCL2+ in the group with complete remission was 40% and in the group without a complete remission of 46.2%. Achieving complete remission was not statistically significantly different between subjects FISH/ BCL-2 positive and negative (χ 2 test, p = 0,585). Frequency FISH/C-MYC in the group with complete remission was 36.7%, while in the group without CR it was 43.8%. Achieving complete remission was not significantly different between patients FISH/ C-MYC positive and negative (χ 2 test, p = 0,570). The frequency of both positive FISH/ BCL-2 and C-MYC, with the presence of at least one positive polymorphism and negative both, it is not statistically significantly different in comparison to achieving a complete remission (χ 2 test, p=0,600). Respondents with BCL-2 and C-MYC negative were slightly over-represented in the group with the complete remission of 43,3%, compared to the patients without complete remission of 31,3%. A bit higher frequency BCL-2 positive patients 31,3% was observed in group without achieving the complete remission, but in patients with complete remission of 20%. The sensitivity observed in the presence of both polymorphisms as well as the sensitivity of FISH positive BCL-2 or C-MYC findings was the same, about 45%. Specificity was the same in the presence BCL-2 or C-MYC gene polymorphism at about 60%, while it was the lowest in the presence both genetic polymorphism
Conclusion
In our study, the sensitivity observed in the presence of both or single mutation was the same, about 45%. Specificity in all observed parameters was relatively small, which means that the absence of the observed risk factors does not mean the emergence of the complete remission. The existence C-MYC and BCL-2 is not a good predictor of achieving complete remission in the era of rituximab.
Session topic: E-poster
Keyword(s): BCL2, C-myc, Fluorescence in situ hybridization, Remission
{{ help_message }}
{{filter}}